Journal
CELL REPORTS MEDICINE
Volume 3, Issue 7, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.xcrm.2022.100686
Keywords
-
Categories
Funding
- NIH [P30-CA54174, GM114102, CA264248, R01ES031522, R01GM140456, I01BX001882, RP190043]
- South Texas Research Laboratory (STRL) Histology-Immunohistochemistry Laboratory
- Neuroendocrine Tumor Research Foundation
- UT System Star Awards
Ask authors/readers for more resources
This study reports a RET::GRB2 fusion in pheochromocytoma, which functions as an oncogenic driver and is sensitive to RET inhibitors, providing a new potential target for therapy in pheochromocytoma.
The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-terminal motifs and is fused to GRB2, a physiological RET interacting protein. RET::GRB2 is an oncogenic driver that leads to constitutive, ligand-independent RET signaling; has transforming capability dependent on RET catalytic function; and is sensitive to RET inhibitors. These observations highlight a new driver event in pheochromo-cytomas potentially amenable for RET-driven therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available